Search PubMedSearch

PubMed · 7964803

Electroencephalography.

Abstract

Notwithstanding recent advances in neuroimaging, EEG remains a major technique for investigation of the brain. Its main applications are in assessment of cerebral function rather than for detecting structural abnormalities. The principal clinical applications are in epilepsy, states of altered consciousness including postanoxic and traumatic coma, the parasomnias, dementias, toxic confusional states, cerebral infections, and various other encephalopathies. Abnormalities in EEG reflect general pathophysiological processes, raised intracranial pressure, cerebral anoxia, or oedema, epileptogenesis etc, and show little specificity for a particular disease. Consequently, they need to be interpreted in a particular clinical context; the use of routine EEG examination for screening purposes is rarely of value. Conversely, the investigation becomes most cost effective when applied to specific problems--for instance, monitoring serial changes in postanoxic coma or during open heart surgery, differential diagnosis (by telemetric ictal recordings) of epileptic and non-epileptic attacks, and providing early prediction of outcome after stroke. High technological standards and an individualised problem solving approach are prerequisites of a cost effective, reliable clinical EEG service. These are most likely to be achieved by a considered, selective referral policy, the use where necessary of prolonged complex procedures such as telemetry, and the avoidance of routine examinations of dubious clinical relevance.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C D Binnie, P F Prior. 1994. Electroencephalography.. https://doi.org/10.1136/jnnp.57.11.1308

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Early progression of disease in HIV-infected infants with thymus dysfunction.

BACKGROUND: Infants with congenital thymic deficiency (the DiGeorge syndrome) have immunodeficiency and a characteristic pattern of low CD4+ and CD8+ T-lymphocyte counts and low CD5+ B-lymphocyte counts. Because the thymus is essential for the generation of CD4+ cells, we sought evidence of thymus dysfunction in infants infected perinatally with the human immunodeficiency virus (HIV). METHODS: We studied the immunophenotypes of 59 infants with maternally transmitted HIV, 5 infants with the DiGeorge syndrome, and 168 infants exposed to HIV but not infected. The criteria for a presumed thymic defect were reductions in both the CD4+ and CD8+ T-cell subgroups during the first six months of life that were confirmed in a subgroup of infants by low counts of CD4+CD45RA+ and CD4+CD45RO+ T cells and CD5+ B cells. RESULTS: Of the 59 HIV-infected infants, 17 had immunophenotypes similar to those of infants with the DiGeorge syndrome. The risks of the acquired immunodeficiency syndrome (AIDS) by the ages of 12 and 24 months were 75 percent and 92 percent in these 17 infants, as compared with 14 and 34 percent in the other 42 infants (P<0.001). Nine of the HIV-infected infants with the DiGeorge-like immunophenotype (53 percent) died within six months of the progression to AIDS, as compared with only three of the other infants (7 percent, P=0.006). CONCLUSIONS: In some infants infected perinatally with HIV, a pattern of lymphocyte depletion develops that resembles the pattern in congenital thymic deficiency. Since HIV disease progresses rapidly in such infants, they may be candidates for early antiviral therapy and attempts at immune reconstitution.

Acquired Immunodeficiency Syndrome

Enhanced HIV-1 activity in bone marrow can lead to myelopoietic suppression partially contributed by gag p24.

Similar to other lymphoid organs, the bone marrow (BM) is a potential reservoir for HIV-1. Although hematologic abnormalities are common in AIDS patients, the mechanisms by which HIV-1 contributes to these abnormalities are poorly understood. Hemapoietic suppression can be mediated by HIV-1 and some of its associated proteins. We have previously reported that AIDS peripheral blood sera inhibit normal CFU-granulocyte macrophage (GM). In this study, we have found that sera obtained from AIDS BM patients are more inhibitory to CFU-GM than those from peripheral blood (p < 0.05). To determine a candidate suppressor factor, we studied the role of p24 and found that it exerts varying degrees of suppression to CFU-GM, but minimal inhibition on erythroid colonies. We have found that the suppressive levels of p24 in in vitro assays are similar to the average circulating levels in AIDS patients. We have also observed that most of the inhibition caused by p24 is mediated by soluble factor(s) produced by the BM stroma. Cross-linking studies with membrane proteins from normal BM stroma and CD34+ cells indicated a putative 26-kDa p24 receptor, indicating that p24 binds to a receptor present on normal BM cells. These results implicate another HIV-1 protein, p24, in hemapoietic suppression and add another plausible mechanism by which HIV-1 contributes to BM failure in AIDS. Furthermore, these findings suggest a potential risk for similar in vivo suppression in the early phase of HIV-1 infection when viremia is elevated, and also in long-term survivors who have low, although persistent, HIV-1 replication.

Acquired Immunodeficiency Syndrome